2024年6月14日 · As we noted in last year’s report, Novo Nordisk and Eli Lilly, competing in the lucrative GLP-1 receptor agonist space that, of late, has captivated the US and beyond in weight loss, are knocking loudly on the top-10 door.Both companies, who own the highest market caps, respectively, in pharma, turned in massive growth in our latest Pharma 50.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

2024年8月2日 · Integrated Delivery Networks have changed the healthcare landscape over the past decade. Greg Skalicky, president and chief revenue officer at EVERSANA, spoke with Pharmaceutical Executive about the ways that commercialization teams are working with these networks to bring drugs to markets.

2024年11月7日 · Donald Trump’s victory in the 2024 US presidential election is sure to have an impact on the pharmaceutical industry. During a panel at the Financial Times’ 2024 Global Pharma and Biotech Summit, the following speakers met to discuss the outcome of the election and the impact it may have on the industry: Lauren Fedor, US political correspondent and Washington deputy bureau chief at The ...

2021年10月11日 · Expanding global access to innovative specialty products is vital to improve patient outcomes and maximize product success. The distribution of these therapies—from the manufacturer’s facility all the way to the site of care—demands flawless execution, as an unbroken temperature chain is essential to both patient safety and product success.

2024年6月7日 · Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe …

2024年1月17日 · The Inflation Reduction Act (IRA), mergers and acquisitions, obesity-control drugs, and artificial intelligence (AI) dominated the pharma industry’s headlines in 2023.

2024年12月20日 · The pharmaceutical industry is undergoing a transformative era, driven by groundbreaking advancements in technology, shifting consumer expectations, and an intensified focus on personalized healthcare solutions.

2024年12月25日 · In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.